The Hospital District of Satakunta
11
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
36%
4 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Promotion of Nurses' Lower Extremity Health by Foot(at)Work Intervention
Role: collaborator
Comparison of Strut Coverage With OPTIMAX Versus SYNERGY Stents
Role: lead
Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome
Role: lead
Vascular Healing After Deployment of Titanium-nitride-oxide-coated OPTIMAX™ Stent and PROMUS-ELEMENT™ Everolimus-Eluting Stent
Role: lead
Vascular Healing of DES at 3 Months
Role: collaborator
Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study)
Role: lead
Titanium Nitride Oxide Coated Stents and Paclitaxel Eluting Stents for Acute Myocardial Infarction
Role: lead
Vessel Wall Response of the Bio-Active-stent and Everolimus-Eluting Stent Assessed By Optical Coherence Tomography
Role: lead
Coronary Flow Reserve in Patients With Bio-active Stent or Everolimus-eluting Stent Implanted in Acute Coronary Syndrome
Role: lead
Comparison of Bio-Active-Stent to the Everolimus-Eluting Stent in Acute Coronary Syndrome
Role: lead
Prevention of Falls and Injurious Falls Among Elderly People
Role: lead
All 11 trials loaded